Get the Stockscreener App
4.938
1.63%
-0.082
Purple Biotech Ltd Adr stock is traded at $4.938, with a volume of 22,966.
It is down -1.63% in the last 24 hours and down -17.34% over the past month.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
See More
Previous Close:
$5.02
Open:
$4.9475
24h Volume:
22,966
Relative Volume:
0.74
Market Cap:
$43.98M
Revenue:
-
Net Income/Loss:
$-19.88M
P/E Ratio:
-5.4264
EPS:
-0.91
Net Cash Flow:
$-19.93M
1W Performance:
-0.84%
1M Performance:
-17.34%
6M Performance:
-25.18%
1Y Performance:
-82.91%
1-Day Range:
$4.825
$5.18
1-Week Range:
$3.98
$5.18
52-Week Range:
$3.98
$30.50
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Compare PPBT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPBT
Purple Biotech Ltd Adr
|
4.87 | 45.33M | 0 | -19.88M | -19.93M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Purple Biotech Ltd Adr Stock (PPBT) Latest News
Purple Biotech Ltd. Sponsored ADR Cash Flow – MUN:1YI0 - TradingView
Total liabilities & shareholders' equities of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
PPBT Earnings History & Surprises | EPS & Revenue Results | PURPLE BIOTECH LTD-ADR (NASDAQ:PPBT) - ChartMill
Purple Biotech Ltd. Sponsored ADR Balance Sheet – MUN:1YI0 - TradingView
Equity in earnings of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
Total debt per share of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Statistics – MUN:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Income Statement – MUN:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Earnings and Revenue – MUN:1YI0 - TradingView
Basic earnings per share (basic EPS) of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Financial Statements – MUN:1YI0 - TradingView
Purple Biotech (PPBT) to Release Quarterly Earnings on Monday - Defense World
Purple Biotech Stock Scheduled to Reverse Split on Monday, March 2nd (NASDAQ:PPBT) - Defense World
Purple Biotech Announces Plan to Implement ADS Ratio Change - ChartMill
Purple Biotech (PPBT) Stock Price, News & Analysis - MarketBeat
Top Ecommerce Stocks To Watch Today – February 16th - Defense World
EverQuote, Inc. (NASDAQ:EVER) Short Interest Up 30.2% in January - Defense World
Short Interest in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Expands By 29.9% - Defense World
Purple Biotech (NASDAQ:PPBT) Shares to Reverse Split on Monday, March 2nd - Defense World
Purple Biotech Ltd. (PPBT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress - GlobeNewswire Inc.
Purple Biotech (NASDAQ:PPBT) Downgraded by Wall Street Zen to Strong Sell - Defense World
Taking on analysts’ expectations and winning: Purple Biotech Ltd ADR (PPBT) - Setenews
Q3 EPS Estimates for Purple Biotech Cut by HC Wainwright - Defense World
A new trading data show nLIGHT Inc (LASR) is showing positive returns. - Setenews
Purple Biotech (PPBT) to Release Quarterly Earnings on Friday - Defense World
An analyst sees good growth prospects for Purple Biotech Ltd ADR (PPBT) - Setenews
So-Young International Inc ADR (SY) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Purple Biotech stock soars after manufacturing milestone for tri-specific antibody By Investing.com - Investing.com South Africa
Purple Biotech stock soars after manufacturing milestone for tri-specific antibody - Investing.com
Dow Surges 250 Points; Verizon Posts Mixed Q3 Results - Benzinga
Is Banco Santander S.A. Sponsored ADR stock a top dividend aristocrat candidateEarnings Recap Report & AI Forecast Swing Trade Picks - newser.com
Purple Biotech Enters New ATM Agreement with H.C. Wainwright - The Globe and Mail
Purple Biotech Ltd. enters $2.3M ATM - Investing.com
Purple Biotech (NASDAQ:PPBT) Trading Down 12.3% – Here’s Why - Defense World
Clinical-Stage Cancer Drug Developer Purple Biotech to Present at Major Healthcare Conference - Stock Titan
Purple Biotech (NASDAQ:PPBT) Trading Down 4.9% Following Weak Earnings - Defense World
Purple Biotech Highlights Clinical Milestones and Pipeline Progress in H1 2025 - TipRanks
Purple Biotech (PPBT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
H.C. Wainwright lifts Purple Biotech stock target to $34 - Investing.com
Purple Biotech appoints Shai Lankry as new CFO - Investing.com
Best upcoming stock splits and reverse splits 2024 - Investorsobserver
PPBT Stock Price and Chart — NASDAQ:PPBT - TradingView — Track All Markets
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy - Nasdaq
Purple Biotech Ltd Share Price ADR Each Representing 200 Ord Shares SPON - Hargreaves Lansdown
PPBT stock touches 52-week low at $5.89 amid market challenges - Investing.com
What Makes Purple Biotech (PPBT) a New Buy Stock - Yahoo Finance
Purple Biotech stock target cut on trial cohort issue - Investing.com
95 Promising Stocks You Can Currently Buy for Less Than $5 Per Share - GOBankingRates
Why Purple Biotech (PPBT) Shares Are Trading Lower - Benzinga
Which stocks are moving before the opening bell on Thursday? - ChartMill
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):